ClinConnect ClinConnect Logo
Search / Trial NCT00737048

A Comparative Study of JNS013 in Participants With Post-Tooth-Extraction Pain

Launched by JANSSEN PHARMACEUTICAL K.K. · Aug 15, 2008

Trial Information

Current as of July 21, 2025

Completed

Keywords

Pain Tooth Extraction Oral Surgery Postoperative Pain Jns013 Tramadol Hydrochloride Acetaminophen

ClinConnect Summary

This is a multi-center (conducted in more than one center), double-blind (neither Physician nor participant knows the name of the assigned drug), randomized (study drug assigned by chance), parallel-group (each group of participant will be treated at the same time) and comparative study in participants having pain intensity of at least 50.0 millimeter (mm) (on visual analog scale, score ranging from 0 mm \[no pain\] to 100 mm \[worst possible pain\]), following extraction of an impacted mandibular wisdom tooth. The study consists of 3 parts: Pre-observation (7 days before study commences on...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Participants planned to receive a tooth extraction of one mandibular impacted wisdom tooth
  • Participants who require bone removal and separation of the crown at tooth extraction
  • Participants whose intensity of pain associated with tooth extraction within 2 hours after tooth extraction is greater than or equal to 50.0 millimeter on the visual analog scale (VAS)
  • Participants who did not undergo general anesthesia or sedation at tooth extraction
  • Participants without an abnormality (including laboratory test values) corresponding to Grade 3 in the "Criteria for severity classification of adverse drug reactions" during the pretreatment observation period
  • Exclusion Criteria:
  • Participants with conditions for which tramadol is contraindicated
  • Participants with conditions for which acetaminophen is contraindicated
  • Participants with history of convulsions or the possibility of convulsive seizures
  • Pregnant participants or those who may be pregnant, lactating mothers, and those who wish pregnancy during the study period
  • Participants with concurrent, previous, or possible alcohol dependence, drug dependence or narcotic addiction

About Janssen Pharmaceutical K.K.

Janssen Pharmaceutical K.K., a subsidiary of Johnson & Johnson, is a leading global pharmaceutical company committed to addressing some of the most pressing healthcare challenges through innovative research and development. With a strong focus on therapeutic areas including immunology, infectious diseases, neuroscience, oncology, and cardiovascular health, Janssen Pharmaceutical K.K. leverages cutting-edge science and technology to deliver transformative treatments. The company is dedicated to advancing medical knowledge and improving patient outcomes through robust clinical trials and collaborations with healthcare professionals, researchers, and institutions worldwide.

Locations

Tokyo, , Japan

Kumamoto, , Japan

Osaka, , Japan

Kitakyushu, , Japan

Sapporo, , Japan

Yokohama, , Japan

Yokosuka, , Japan

Isehara, , Japan

Shimotsuke, , Japan

Ohta Ku, , Japan

Shimotsuga, , Japan

Yokohama N/A, , Japan

Patients applied

0 patients applied

Trial Officials

Janssen Pharmaceutical K.K., Japan Clinical Trial

Study Director

Janssen Pharmaceutical K.K.

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials